Breaking Down Endo Health's Brilliant Buyout

From the smallest biotech to the biggest pharmaceutical stock The Motley Fool's Market Checkup covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.

In this segment from Tuesday's episode, shares of Endo Health (NASDAQ: ENDP  ) soared after the company announced it is buying the Canada-based Paladin Labs for $1.5 billion. Motley Fool health-care analyst David Williamson takes a close look at the deal and tells investors why the market reacted so favorably and whether he sees this as a good time to buy.

More Foolish insight
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

 

Follow David on Twitter @MotleyDavid.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2719785, ~/Articles/ArticleHandler.aspx, 7/22/2014 4:34:38 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement